Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin modulatorsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockers
TargetsMesothelinProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Cell Therapy Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Research Institute
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A